Precision glycoengineering and delivery of biologics
We strive to ensure our pipeline of development for biopharmaceuticals is second to none. Below you can learn more about our project portfolio focus, our programs, and our results.
Our development innovations
Our development process includes biopharmaceutical solutions for a wide range of medical uses. Our pipeline of development has designed innovations that include:
Serpins as therapeutics:
The Serpin genes represent the largest class of glycoprotein serine protease inhibitors, including more than 70 different enzymes, 37 of which are found in humans. These enzymes are single-use proteins that undergo unique and extensive conformational changes to inhibit proteases and proteolytic cascades. There are diverse indications where these enzymes are needed as therapeutics ranging from chronic obstructive pulmonary disease to thrombosis and cancer. Their potent activities and human compatibility make them invaluable therapeutics. However, these protease inhibitors' single-use nature makes it essential that their activity and half-life are optimized to improve dosing and efficacy. Here at NeuImmune, we optimize the Serpin family enzymes and their glycan post-translational modifications, leading with Antithrombin, where the only available treatment for patients are plasma-derived therapeutics.
Hep C vaccine
NeuImmune's second promising product is a vaccine against the Hepatitis C virus (HCV). The CDC estimates that 3-4 million people are infected in the U.S. alone with HCV. Many of these patients are undiagnosed, resulting in significant morbidity from liver cirrhosis and hepatocellular carcinoma associated with HCV infections. While direct-acting antivirals are highly effective in treating HCV infections once diagnosed, NeuImmune believes that there is a significant market for a prophylactic vaccine against HCV.
